IMA
NASDAQImageneBio Inc.
News25/Ratings3
News · 26 weeks57+150%
2026-03-012026-08-23
Mix2990d
- SEC Filings15(52%)
- Insider9(31%)
- Other3(10%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- ANALYSTH.C. Wainwright initiated coverage on ImageneBio with a new price targetH.C. Wainwright initiated coverage of ImageneBio with a rating of Buy and set a new price target of $28.00
- INSIDERChief Executive Officer Yarema Kristin was granted 254,800 shares, increasing direct ownership by 107% to 493,705 units (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERChief Financial Officer Grant-Huerta Yanina was granted 104,000 shares (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- PRImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of 79,000 restricted stock units ("RSUs") and 56,525 non-qualified stock options ("NSOs") to three newly hired non-executive employees. Additionally, the Compensation Committee granted inducement awards consisting of 65,000 RSUs and 56,000 NSOs to Yanina Grant-Huerta, our Chief Financial Officer. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imag
- SECSEC Form EFFECT filed by ImageneBio Inc.EFFECT - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form EFFECT filed by ImageneBio Inc.EFFECT - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form EFFECT filed by ImageneBio Inc.EFFECT - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form S-8 filed by ImageneBio Inc.S-8 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form S-3 filed by ImageneBio Inc.S-3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form POS AM filed by ImageneBio Inc.POS AM - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form S-3 filed by ImageneBio Inc.S-3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 10-Q filed by ImageneBio Inc.10-Q - ImageneBio, Inc. (0001835579) (Filer)
- SECImageneBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio Reports Second Quarter 2026 Financial ResultsSAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highlights Olevaprubart, also known as IMG-007, the potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti-OX40 receptor antagonist with an extended half-life. The Phase 2b ADAPTIVE trial of olevaprubart in moderate-to-severe atopic dermatitis continues to progress as planned under the amended protocol.A long-term extension (LTE) study has been opened for patients enrolled in ADAPTIVE and sites are actively enrolling patie
- INSIDERSEC Form 3 filed by new insider Grant-Huerta Yanina3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERChief Executive Officer Yarema Kristin converted options into 38,376 shares and acquired 115,129 shares, increasing direct ownership by 180% to 238,905 units (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by ImageneBio Inc.8-K - ImageneBio, Inc. (0001835579) (Filer)
- INSIDERPrincipal Accounting Officer Lally Robert B sold $17,334 worth of shares (3,196 units at $5.42), decreasing direct ownership by 5% to 55,582 units (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- PRImageneBio Appoints Matt Robbins as General CounselSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene" or the "Company")), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions, providing strategic counsel as the Company advances its lead candidate, IMG-007. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, PhD, Chief Executive Officer of Imagene. "Matt’s experience building a legal function inside a clinical-
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by ImageneBio Inc.8-K - ImageneBio, Inc. (0001835579) (Filer)
- INSIDERSEC Form 4 filed by Director Bonita David P4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Director Wang Jonathan Jian4 - ImageneBio, Inc. (0001835579) (Issuer)
IMA FAQ
6 questionsWhere does IMA stock trade?
ImageneBio Inc. (IMA) is listed on NASDAQ.What sector and industry is IMA in?
ImageneBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImageneBio Inc. go public?
ImageneBio Inc. (IMA) completed its IPO in 2021.What are analysts saying about IMA?
ImageneBio Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $2800.00 price target on 2026-08-21.What companies are similar to IMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IMA side-by-side with any of them on Quantisnow.How can I track IMA on Quantisnow?
Quantisnow aggregates ImageneBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMA to receive live email and push alerts on every new disclosure.